Heart Failure Outpatient Preserved Ejection Fraction 
JAMA Cardiology
FEBRUARY 25, 2025
This secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial evaluates the effect of finerenone on outpatient worsening heart failure events requiring oral diuretic intensification among patients with heart failure with mildly reduced or (..)
Frontiers in Cardiovascular Medicine
JANUARY 26, 2025
This proof-of-principle study investigates the association between tissue sodium content, assessed by MRI, and HF-related baseline parameters in an outpatient cohort of patients with chronic heart failure, including those with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF).Methods
Circulation
JANUARY 22, 2025
Circulation, Ahead of Print.
The British Journal of Cardiology
JANUARY 16, 2024
Heart failure with preserved ejection fraction (HFpEF) is a common concern in the medical field due to its prevalence in an ageing western population. HFpEF is associated with significant morbidity and mortality not dissimilar to heart failure (HF) with reduced ejection fraction.
Open Heart
NOVEMBER 4, 2022
Introduction The diagnostic and therapeutic arsenal for heart failure with preserved ejection (HFpEF) has expanded. With novel therapies (eg, sodium-glucose co-transporter 2 inhibitors) and firmer recommendations to optimise non-cardiac comorbidities, it is unclear if outpatient HFpEF models can adequately deliver this.
Circulation
AUGUST 4, 2024
Circulation, Volume 150, Issue 6 , Page e106-e106, August 6, 2024.
Circulation
AUGUST 4, 2024
Circulation, Volume 150, Issue 6 , Page e107-e108, August 6, 2024.
Expert insights. Personalized for you.
111 
Let's personalize your content